FFIV Quote, Financials, Valuation and Earnings

Dynatrace has a net margin of 22.14% compared to F5's net margin of 10.53%. F5's return on equity of 19.23% beat Dynatrace's return on equity of 8.21%.

F5 has a consensus price target of $242.86, signalling downside risk potential of -5.61%. On the other hand Dynatrace has an analysts' consensus of $62.21 which suggests that it could grow by 19.05%. Given that Dynatrace has higher upside potential than F5, analysts believe Dynatrace is more attractive than F5.

F5 has a beta of 1.057, which suggesting that the stock is 5.653% more volatile than S&P 500. In comparison Dynatrace has a beta of 1.023, suggesting its more volatile than the S&P 500 by 2.307%.

F5 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynatrace offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. F5 pays -- of its earnings as a dividend. Dynatrace pays out -- of its earnings as a dividend.

F5 quarterly revenues are $746.7M, which are larger than Dynatrace quarterly revenues of $418.1M. F5's net income of $165.3M is higher than Dynatrace's net income of $44M. Notably, F5's price-to-earnings ratio is 26.91x while Dynatrace's PE ratio is 95.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for F5 is 5.42x versus 10.06x for Dynatrace. Usually stocks with elevated PS ratios are considered overvalued.

Enfusion has a net margin of 22.14% compared to F5's net margin of 2.77%. F5's return on equity of 19.23% beat Enfusion's return on equity of 3.97%.

F5 has a consensus price target of $242.86, signalling downside risk potential of -5.61%. On the other hand Enfusion has an analysts' consensus of $9.89 which suggests that it could fall by -2.63%. Given that F5 has more downside risk than Enfusion, analysts believe Enfusion is more attractive than F5.

F5 has a beta of 1.057, which suggesting that the stock is 5.653% more volatile than S&P 500. In comparison Enfusion has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

F5 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enfusion offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. F5 pays -- of its earnings as a dividend. Enfusion pays out -- of its earnings as a dividend.

F5 quarterly revenues are $746.7M, which are larger than Enfusion quarterly revenues of $51.2M. F5's net income of $165.3M is higher than Enfusion's net income of $1.4M. Notably, F5's price-to-earnings ratio is 26.91x while Enfusion's PE ratio is 254.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for F5 is 5.42x versus 6.18x for Enfusion. Usually stocks with elevated PS ratios are considered overvalued.

GitLab has a net margin of 22.14% compared to F5's net margin of 15.08%. F5's return on equity of 19.23% beat GitLab's return on equity of -7.4%.

F5 has a consensus price target of $242.86, signalling downside risk potential of -5.61%. On the other hand GitLab has an analysts' consensus of $80.09 which suggests that it could grow by 32.23%. Given that GitLab has higher upside potential than F5, analysts believe GitLab is more attractive than F5.

F5 has a beta of 1.057, which suggesting that the stock is 5.653% more volatile than S&P 500. In comparison GitLab has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

F5 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GitLab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. F5 pays -- of its earnings as a dividend. GitLab pays out -- of its earnings as a dividend.

F5 quarterly revenues are $746.7M, which are larger than GitLab quarterly revenues of $196M. F5's net income of $165.3M is higher than GitLab's net income of $29.6M. Notably, F5's price-to-earnings ratio is 26.91x while GitLab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for F5 is 5.42x versus 13.80x for GitLab. Usually stocks with elevated PS ratios are considered overvalued.

Lyft has a net margin of 22.14% compared to F5's net margin of -0.82%. F5's return on equity of 19.23% beat Lyft's return on equity of -11.93%.

F5 has a consensus price target of $242.86, signalling downside risk potential of -5.61%. On the other hand Lyft has an analysts' consensus of $19.27 which suggests that it could grow by 34.53%. Given that Lyft has higher upside potential than F5, analysts believe Lyft is more attractive than F5.

F5 has a beta of 1.057, which suggesting that the stock is 5.653% more volatile than S&P 500. In comparison Lyft has a beta of 2.144, suggesting its more volatile than the S&P 500 by 114.381%.

F5 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyft offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. F5 pays -- of its earnings as a dividend. Lyft pays out -- of its earnings as a dividend.

F5 quarterly revenues are $746.7M, which are smaller than Lyft quarterly revenues of $1.5B. F5's net income of $165.3M is higher than Lyft's net income of -$12.4M. Notably, F5's price-to-earnings ratio is 26.91x while Lyft's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for F5 is 5.42x versus 1.06x for Lyft. Usually stocks with elevated PS ratios are considered overvalued.